dr. mcdermott discusses pd-l1 expression in kidney cancer
Published 10 years ago • 102 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
0:51
dr. mcdermott on pd-l1 expression in non-clear cell renal cell cancer
-
5:18
pd-l1 expression as a biomarker in renal cell carcinoma
-
2:16
optimal targeting in metastatic kidney cancer - dr. david mcdermott asco 2014
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
3:16
what is pd1 and pdl1 in kidney cancer?
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
35:00
t cell checkpoint inhibitors in rcc: a new hope? david f. mcdermott, m.d.
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
8:43
immunotherapy in renal cell carcinoma
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
10:55
ucla's dr. antoni ribas discusses pd1 and pd-l1 targeted cancer drugs
-
2:22
are there pd1 biomarkers in kidney cancer?